TGM2 and neoplasm: When the 475 untreated lymph-node negative patients from the METABRIC dataset were stratified using the TGM2 expression median value as cutoff, no differences in DSS were observed by survival analysis both considering all patients or by separately analyzing the patients subdivided according to their tumor molecular subtype.